Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03940820 |
Title针对实体瘤患者的 ROBO1 特异性 CAR-NK 细胞临床研究 | 阶段
第 1 阶段/第 2 阶段
|
Date Added 2019-05-07 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
ROBO1 CAR-NK 细胞 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03795311 |
Title评估 FOLFIRINOX3 贝伐单抗治疗结直肠癌患者的疗效和安全性（FOLFIRINOX 3） | 阶段
Phase 1, Phase 2
|
Date Added 2019-01-07 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
FOLFIRINOX 贝伐单抗 |
标签
MSS/ MMRp
|
| NCT ID NCT03874897 |
Title在实体瘤中靶向 claudin18.2 的嵌合抗原受体 T 细胞。 | 阶段
第 1 阶段
|
Date Added 2019-03-14 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
CAR-CLDN18.2 T-Cells, Chemotherapy, PD-1 Monoclonal Antibody |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04046445 |
Title对 IV 期结直肠癌患者进行 ATP128、VSV-GP128 和 BI 754091 评估的 1b 期研究 | 阶段
第 1 阶段
|
Date Added 2019-08-06 |
地点
Arizona, United States
California, United States Colorado, United States New York, United States North Carolina, United States Texas, United States 比利时 德国 瑞士 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
ATP128, BI 754091, VSV-GP128 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03867799 |
TitleiSCORE: Immunotherapy Sequencing in COlon and REctal Cancer | 阶段
第二阶段
|
Date Added 2019-03-08 |
地点
英国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT02499328 |
TitleStudy to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck | 阶段
Phase 1, Phase 2
|
Date Added 2015-07-16 |
地点
Alabama, United States
California, United States Colorado, United States Florida, United States Indiana, United States Massachusetts, United States Michigan, United States Montana, United States New Jersey, United States Ohio, United States Texas, United States Virginia, United States Washington, United States 比利时 德国 意大利 西班牙 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
AZD5069, AZD9150, MEDI4736, tremelimumab (treme) |
标签
MSS/ MMRp
|
| NCT ID NCT04017650 |
TitleEncorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2019-07-12 |
地点
Texas, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, encorafenib, Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT03711058 |
TitleStudy of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2018-10-18 |
地点
Maryland, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Copanlisib, Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT05167409 |
TitleA Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2021-12-22 |
地点
Arizona, United States
Colorado, United States New Jersey, United States Virginia, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
ALX148, cetuximab, Evorpacept (ALX148), Pembrolizumab, Erbitux, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT03727763 |
Title西妥昔单抗和维莫非尼联合 FOLFIRI 治疗 BRAF V600E 突变的晚期结直肠癌 (IMPROVEMENT) | 阶段
第二阶段
|
Date Added 2018-11-01 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
cetuximab, Vemurafenib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
